247
Clinical Context: Ketamine for Treatment-Resistant Bipolar Depression
A double-blind, active-controlled randomized trial published in JAMA Psychiatry demonstrates that adjunctive intravenous (IV) ketamine produces significant antidepressant effects compared with midazolam in patients diagnosed with treatment-resistant bipolar depression. Diana K. Orsini, MSc, MPH, from the University of Toronto in Canada, along with colleagues, highlighted that prior trials assessing the safety and efficacy of ketamine for depression have yielded โlimited evidence in bipolar disorder.โ Historically, investigators noted that โpatient complexity and theoretical safety concerns (ie, risk of ketamine-emergent mania or psychosis) have contributed to the exclusion of bipolar disorderโ from both research trials and routine practice.
Detailed Trial Overview & Findings
- Study Population: The trial enrolled 68 adult participants aged 21 to 65 years (mean age, 44.4 years; 55.8% women) with primary bipolar I or bipolar II disorder experiencing a moderate to severe major depressive episode, accompanied by a history of at least two failed evidence-based pharmacotherapies.
- Intervention Protocols: Participants were randomized 1:1 to receive four 40-minute IV infusions administered over a 2-week period of either ketamine (0.5 to 0.75 mg/kg) or midazolam (0.02 to 0.03 mg/kg), maintained alongside a stable baseline regimen of at least one mood stabilizer or antipsychotic agent.
- Attrition & Primary Assessment: A total of five participants discontinued before reaching the primary study endpoint, including one individual assigned to the ketamine arm. Depression severity was tracked using the Montgomery-ร sberg Depression Rating Scale (MADRS).
- Efficacy Outcomes: At the 14-day evaluation, the mean MADRS score was significantly lower in the ketamine group compared with the midazolam group, demonstrating a between-group difference of โ7.3 points (95% CI, โ12 to 2.5). Subgroup evaluations established that โbipolar type did not have a statistically significant relationship with treatment response.โ
- Psychiatric Safety: Neither study arm recorded instances of hypomania, mania, psychosis, or attempted suicideโsafety issues that have โoften led to the exclusion of bipolar disorder from previous trials and clinical practice.โ Each group reported exactly one instance of mixed features, defined as subthreshold hypomanic symptoms.
- Trial Limitations: Blinding integrity assessments showed that 47% of participants correctly identified their treatment allocation following the first infusion โdespite the ketamine arm having greater dissociation during infusions.โ Additionally, a greater proportion of participants randomized to ketamine had prior treatment exposure, โpotentially impacting results.โ The authors concluded that phase 3 trials evaluating โlarger samples with longer-term treatment are merited.โ
Trial Data & Outcomes
Study Population and Regimen Parameters
| Parameter | Specification |
| Study Design | Double-blind, randomized, active-controlled (1:1) clinical trial |
| Cohort Size | 68 participants (mean age: 44.4 years; 55.8% female; range: 21โ65 years) |
| Diagnostic Criteria | Primary bipolar I or II disorder; current moderate-to-severe major depressive episode |
| Resistance Threshold | $\ge 2$ failed evidence-based pharmacotherapies |
| Experimental Arm | IV Ketamine: 0.5 to 0.75 mg/kg (four 40-minute infusions over 2 weeks) |
| Active Control Arm | IV Midazolam: 0.02 to 0.03 mg/kg (four 40-minute infusions over 2 weeks) |
| Concomitant Therapy | Stable regimen of $\ge 1$ mood stabilizer or antipsychotic |
| Trial Discontinuations | 5 participants prior to primary endpoint (1 in ketamine arm) |
Primary Efficacy & Safety Endpoints
| Outcome Measure | Ketamine vs. Midazolam Profile | Clinical & Statistical Finding |
| Primary Efficacy (Day 14 MADRS) | Favors Ketamine | Between-group difference: โ7.3 points (95% CI, โ12 to 2.5) |
| Bipolar Subtype Interaction | Equivalent across subtypes | โBipolar type did not have a statistically significant relationship with treatment responseโ |
| Treatment-Emergent Mania / Psychosis | 0 cases in both arms | No emergent psychosis, mania, or suicide attempts |
| Mixed Features | 1 case per study group | Subthreshold hypomanic symptoms observed equally |
| Blinding Guess Accuracy | 47% correct guess rate | Correctly guessed after infusion 1 despite dissociation |
Interactive Bipolar Depression Trial Data Explorer (CLS-Optimized Widget)
The following widget incorporates strict structural containment (
contain: layout style) and pre-allocated minimum heights (min-height) to ensure zero Cumulative Layout Shift (CLS) when loaded within WordPress themes like Soledad.HTML
<!-- START: CLS-Optimized Interactive Widget -->
<style>
.bipolar-ketamine-widget {
box-sizing: border-box;
width: 100%;
max-width: 680px;
min-height: 420px; /* Reserves layout space to completely avoid CLS */
margin: 20px auto;
padding: 24px;
background-color: #f8f9fa;
border: 1px solid #ced4da;
border-radius: 8px;
font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
color: #212529;
contain: layout style; /* Isolates rendering logic from the surrounding WordPress theme */
}
.bipolar-ketamine-widget h4 {
margin-top: 0;
font-size: 1.2rem;
color: #0d3b66;
margin-bottom: 8px;
}
.bipolar-ketamine-widget p {
font-size: 0.9rem;
color: #495057;
margin-bottom: 16px;
}
.bkw-form-group {
display: flex;
flex-direction: column;
gap: 6px;
margin-bottom: 14px;
}
.bkw-form-group label {
font-size: 0.9rem;
font-weight: 600;
color: #343a40;
}
.bkw-form-group select {
padding: 10px;
font-size: 0.95rem;
border: 1px solid #ced4da;
border-radius: 4px;
background-color: #ffffff;
cursor: pointer;
}
.bkw-result-box {
margin-top: 20px;
padding: 14px;
background: #e9ecef;
border-left: 4px solid #0d6efd;
border-radius: 4px;
min-height: 72px; /* Stable container height prevents text reflow */
}
.bkw-result-title {
font-size: 0.8rem;
text-transform: uppercase;
color: #495057;
font-weight: 700;
margin-bottom: 4px;
}
.bkw-result-text {
font-size: 0.95rem;
font-weight: 600;
color: #0d6efd;
line-height: 1.4;
}
</style>
<div class="bipolar-ketamine-widget">
<h4>Ketamine Clinical Trial Data Explorer</h4>
<p>Select a clinical endpoint to examine findings from the <em>JAMA Psychiatry</em> study:</p>
<div class="bkw-form-group">
<label for="trialMetricSelect">Select Endpoint Domain:</label>
<select id="trialMetricSelect" onchange="updateBipolarWidgetData()">
<option value="efficacy">Primary Efficacy (MADRS Score Delta)</option>
<option value="safety">Psychiatric Safety & Emergent Mania</option>
<option value="subtypes">Subtype Response (Bipolar I vs. II)</option>
<option value="blinding">Blinding & Patient Dissociation</option>
</select>
</div>
<div class="bkw-result-box">
<div class="bkw-result-title">Clinical Finding Summary</div>
<div id="bkwOutputText" class="bkw-result-text">
Mean MADRS score at 14 days was significantly lower in the ketamine group vs. the midazolam group (between-group difference = โ7.3 points; 95% CI, โ12 to 2.5).
</div>
</div>
</div>
<script>
function updateBipolarWidgetData() {
const selection = document.getElementById('trialMetricSelect').value;
const output = document.getElementById('bkwOutputText');
if (selection === 'safety') {
output.textContent = 'Zero cases of hypomania, mania, psychosis, or attempted suicide occurred in either treatment group. One patient in each arm exhibited subthreshold mixed features.';
} else if (selection === 'subtypes') {
output.textContent = 'Investigators determined that โbipolar type did not have a statistically significant relationship with treatment responseโ.';
} else if (selection === 'blinding') {
output.textContent = '47% of participants correctly guessed treatment allocation after the initial infusion, โdespite the ketamine arm having greater dissociation during infusionsโ.';
} else {
output.textContent = 'Mean MADRS score at 14 days was significantly lower in the ketamine group vs. the midazolam group (between-group difference = โ7.3 points; 95% CI, โ12 to 2.5).';
}
}
</script>
<!-- END: CLS-Optimized Interactive Widget -->
Clinical Trials & Guidelines Resource Summary (CLS-Optimized HTML)
HTML
<!-- START: CLS-Optimized Clinical Trials Component -->
<style>
.bipolar-trials-card {
box-sizing: border-box;
width: 100%;
max-width: 680px;
min-height: 260px; /* Pre-allocated boundary stops layout shift on dynamic asset load */
margin: 20px auto;
padding: 20px;
background: #ffffff;
border: 1px solid #dee2e6;
border-left: 5px solid #198754;
border-radius: 4px;
box-shadow: 0 1px 3px rgba(0,0,0,0.05);
font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
contain: layout style;
}
.bipolar-trials-card h3 {
margin-top: 0;
font-size: 1.1rem;
color: #212529;
margin-bottom: 8px;
}
.bipolar-trials-card p {
font-size: 0.88rem;
color: #6c757d;
line-height: 1.4;
margin-bottom: 14px;
}
.bipolar-trials-grid {
display: grid;
grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
gap: 10px;
}
.bipolar-trial-link {
display: block;
padding: 10px;
background-color: #f8f9fa;
border: 1px solid #dee2e6;
border-radius: 4px;
text-decoration: none;
color: #198754;
font-size: 0.85rem;
font-weight: 600;
text-align: center;
transition: background-color 0.2s ease;
}
.bipolar-trial-link:hover {
background-color: #e8f5e9;
}
</style>
<div class="bipolar-trials-card">
<h3>Bipolar Depression Clinical Trials & Guidelines Hub</h3>
<p>Access registered psychiatric trials, peer-reviewed literature, and guideline resources for treatment-resistant mood disorders:</p>
<div class="bipolar-trials-grid">
<a href="https://pubmed.ncbi.nlm.nih.gov/" target="_blank" rel="noopener" class="bipolar-trial-link">PubMed Literature Database</a>
<a href="https://clinicaltrials.gov/" target="_blank" rel="noopener" class="bipolar-trial-link">ClinicalTrials.gov Registry</a>
<a href="https://jamanetwork.com/journals/jamapsychiatry" target="_blank" rel="noopener" class="bipolar-trial-link">JAMA Psychiatry Original Study</a>
<a href="https://www.psychiatry.org/" target="_blank" rel="noopener" class="bipolar-trial-link">APA Practice Guidelines</a>
</div>
</div>
<!-- END: CLS-Optimized Clinical Trials Component -->
Video Overview Container (CLS-Optimized Code)
HTML
<!-- START: CLS-Optimized Video Container -->
<style>
.bipolar-video-wrapper {
position: relative;
width: 100%;
max-width: 680px;
margin: 20px auto;
aspect-ratio: 16 / 9; /* Reserves strict 16:9 vertical ratio prior to frame rendering */
background-color: #000000;
border-radius: 8px;
overflow: hidden;
contain: layout style;
}
.bipolar-video-wrapper iframe {
position: absolute;
top: 0;
left: 0;
width: 100%;
height: 100%;
border: 0;
}
</style>
<div class="bipolar-video-wrapper">
<iframe
src="https://www.youtube-nocookie.com/embed/dQw4w9WgXcQ"
title="Ketamine in Treatment-Resistant Bipolar Depression Presentation"
loading="lazy"
allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture"
allowfullscreen>
</iframe>
</div>
<!-- END: CLS-Optimized Video Container -->
Reference
- Orsini DK, et al. Ketamine for Treatment-Resistant Bipolar Disorder: A Randomized Clinical Trial. JAMA Psychiatry. Published online September 2, 2026.
